PE20091971A1 - Formulaciones orales de analogos de citidina y metodos de uso de los mismos - Google Patents

Formulaciones orales de analogos de citidina y metodos de uso de los mismos

Info

Publication number
PE20091971A1
PE20091971A1 PE2009000685A PE2009000685A PE20091971A1 PE 20091971 A1 PE20091971 A1 PE 20091971A1 PE 2009000685 A PE2009000685 A PE 2009000685A PE 2009000685 A PE2009000685 A PE 2009000685A PE 20091971 A1 PE20091971 A1 PE 20091971A1
Authority
PE
Peru
Prior art keywords
composition
methods
same
citidine
refers
Prior art date
Application number
PE2009000685A
Other languages
English (en)
Inventor
Jeffrey B Etter
Mei Lai
Jay Thomas Backstrom
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091971(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PE20091971A1 publication Critical patent/PE20091971A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION PARA LA LIBERACION INMEDIATA, QUE COMPRENDE: A) 5-ACETIDINA; B) UN INTENSIFICADOR DE LA PERMEABILIDAD TAL COMO D-ALFA TOCOFERIL POLIETILENGLICOL 1000 SUCCINATO EN UNA PROPORCION DE 2% POR PESO; C) EXCIPIENTES SELECCIONADO DE MANITOL, CELULOSA MICROCRISTALINA, CROSPOVIODNA Y ESTEARATO DE MAGNESIO. LA COMPOSICION ESTA ESENCIALMENTE LIBRE DE UN INHIBIDOR DE DEAMINASA DE CITIDINA Y TETRAHIDROURIDINA. TAMBIEN SE REFIERE A UN METODO DE PREPARACION PARA LA ADMINISTRACION ORAL DE RECUBIERTA NO ENTERICA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA PROLIFERACION ANORMAL DE CELULAS TAL COMO SINDROME MIELODISPLASICO O LEUCEMIA MIELOGINOSA AGUDA
PE2009000685A 2008-05-15 2009-05-15 Formulaciones orales de analogos de citidina y metodos de uso de los mismos PE20091971A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05

Publications (1)

Publication Number Publication Date
PE20091971A1 true PE20091971A1 (es) 2010-01-15

Family

ID=40941609

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2014002005A PE20142440A1 (es) 2008-05-15 2009-05-15 Composiciones farmaceuticas orales de liberacion inmediata con recubrimiento no enterico que comprende 5-azacitidina
PE2009000685A PE20091971A1 (es) 2008-05-15 2009-05-15 Formulaciones orales de analogos de citidina y metodos de uso de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2014002005A PE20142440A1 (es) 2008-05-15 2009-05-15 Composiciones farmaceuticas orales de liberacion inmediata con recubrimiento no enterico que comprende 5-azacitidina

Country Status (34)

Country Link
US (12) US8846628B2 (es)
EP (6) EP4327888A3 (es)
JP (3) JP2011520880A (es)
KR (1) KR101633134B1 (es)
CN (3) CN102099018B (es)
AR (1) AR071808A1 (es)
AU (3) AU2009246926B2 (es)
BR (1) BRPI0912717A2 (es)
CA (3) CA3094590A1 (es)
CL (2) CL2009001170A1 (es)
CO (1) CO6300930A2 (es)
CR (1) CR11789A (es)
CY (3) CY1121350T1 (es)
DK (5) DK3692983T3 (es)
EC (1) ECSP10010665A (es)
ES (5) ES2969144T3 (es)
FI (1) FI3782612T3 (es)
HR (5) HRP20190100T1 (es)
HU (5) HUE055911T2 (es)
IL (2) IL238087B (es)
LT (5) LT3782611T (es)
MX (2) MX2010012470A (es)
MY (1) MY161593A (es)
NI (1) NI201000193A (es)
NZ (3) NZ623495A (es)
PE (2) PE20142440A1 (es)
PL (5) PL2695609T3 (es)
PT (5) PT3692983T (es)
RU (2) RU2476207C2 (es)
SG (1) SG193206A1 (es)
SI (5) SI3782612T1 (es)
TW (3) TW201513869A (es)
WO (1) WO2009139888A1 (es)
ZA (1) ZA201008229B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
CA2742252A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
JP6063628B2 (ja) * 2009-02-10 2017-01-18 セルジーン インターナショナル サルル ５−アザシチジンを用いる、非小細胞肺癌の治療方法
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
MY166014A (en) * 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
JP2014503597A (ja) 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
JP6289361B2 (ja) 2011-03-31 2018-03-07 セルジーン インターナショナル サルル ５−アザシチジンの合成
TW201700103A (zh) 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法
US8980850B2 (en) 2011-11-03 2015-03-17 Millennium Pharmaceuticals, Inc. Administration of a NEDD8-activating enzyme inhibitor and hypomethylating agent
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX2015000804A (es) * 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
US10202579B2 (en) * 2012-11-29 2019-02-12 Takara Bio Europe Ab Methods for producing mammalian pluripotent stem cell-derived endodermal cells
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US20150359810A1 (en) * 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US10034872B2 (en) 2014-08-22 2018-07-31 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
KR20180008511A (ko) * 2015-05-22 2018-01-24 노파르티스 아게 제약 조성물
DK3362066T3 (da) * 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
MX381582B (es) * 2015-10-15 2025-03-12 Celgene Corp Terapia de combinacion para el tratamiento de neoplasias malignas.
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
CA3007357C (en) 2015-12-03 2023-12-05 Epidestiny, Inc. Compositions containing decitabine, 5azacytidine and tetrahydrouridine and uses thereof
WO2017180489A1 (en) 2016-04-12 2017-10-19 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic dna or rna
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
WO2020257671A1 (en) * 2019-06-20 2020-12-24 Celgene Corporation Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
WO2021062061A1 (en) * 2019-09-25 2021-04-01 Aardvark Therapeutics Inc. Oral pharmaceutical immediate release composition and method of treatment for weight loss
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
CA3158298A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
WO2021125261A1 (ja) * 2019-12-18 2021-06-24 一般社団法人 東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
ES3036307T3 (en) * 2019-12-31 2025-09-17 Jiangsu Yahong Meditech Co Ltd Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
CA3176543A1 (en) 2020-04-23 2021-10-28 Mark J. Suto Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof
JP7679452B2 (ja) 2020-07-23 2025-05-19 サウザーン リサーチ インスチチュート ５－アザ－４’－チオ－２’－デオキシシチジンの多形
US20240102100A1 (en) * 2020-11-27 2024-03-28 Centre Leon Berard Ribosomal rnas 2'o-methylation as a novel source of biomarkers relevant for diagnosis, prognosis and therapy of cancers
EP4262812A4 (en) 2020-12-18 2025-07-09 Southern Res Inst 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR THE TREATMENT OF VIRAL INFECTIONS
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
CN118354759A (zh) 2021-10-19 2024-07-16 阿基拉比奥有限公司 包含2’-脱氧胞苷类似物的组合物及其用于治疗镰状细胞病、地中海贫血和癌症的用途
AR134497A1 (es) 2023-11-28 2026-01-21 Sanofi Sa Combiterapia multifuncional con activador de los linfocitos citolíticos naturales (nk) para tratar trastornos neoplásicos hemáticos
WO2026068588A1 (en) 2024-09-30 2026-04-02 Synthon B.V. Improved azacitidine composition
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (es) * 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) * 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) * 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) * 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) * 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
DK0397042T3 (da) 1989-05-10 1995-10-02 Hoffmann La Roche Fremstilling af isoquinolinderivater
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) * 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
AU738170B2 (en) * 1996-10-16 2001-09-13 Icn Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
ES2248908T7 (es) 1997-06-06 2014-11-24 Depomed, Inc. Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
CN1361694A (zh) * 1999-07-16 2002-07-31 天藤制药株式会社 粘膜吸收甘草甜素制剂
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1251832E (pt) * 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
GB0102342D0 (en) * 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2002098420A1 (en) 2001-06-01 2002-12-12 Cytovia, Inc. 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) * 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
AU2003278904A1 (en) * 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2503150A1 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
AU2003303373B8 (en) 2002-12-18 2010-06-10 Cytovia, Inc. 3,5-disubstituted-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
MXPA05012464A (es) 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
JP2007504131A (ja) * 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
WO2006089290A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience Inc.. Combinations and modes of administration of therapeutic agents and combination therapy
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
US20080057086A1 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) * 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
US20080182806A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
BRPI0817234A2 (pt) 2007-09-26 2014-09-30 Sinai School Medicine Análogos de azacitidina e seus usos
EP2048151A1 (en) * 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CA2742252A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
HUE055911T2 (hu) 2008-05-15 2021-12-28 Celgene Corp Citidin-analógokat tartalmazó orális készítmények, és eljárások azok alkalmazására
WO2010014883A2 (en) * 2008-08-01 2010-02-04 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
EP2324042B1 (en) * 2008-08-06 2012-11-28 Sicor, Inc. Process for preparing azacytidine intermediate
AU2009279461B2 (en) * 2008-08-08 2014-01-23 Scinopharm Taiwan, Ltd. Process for making 5-azacytosine nucleosides and their derivatives
PL2752189T3 (pl) 2008-11-22 2017-04-28 F. Hoffmann-La Roche Ag Zastosowanie przeciwciała anty-VEGF w połączeniu z chemioterapią do leczenia raka sutka
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) * 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
JP2014503597A (ja) * 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
JP6289361B2 (ja) 2011-03-31 2018-03-07 セルジーン インターナショナル サルル ５−アザシチジンの合成
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
TW201700103A (zh) * 2011-11-01 2017-01-01 西建公司 利用胞嘧啶核苷類似物之口服配方治療癌症的方法

Also Published As

Publication number Publication date
DK3692983T3 (da) 2021-09-20
CO6300930A2 (es) 2011-07-21
US20200101095A1 (en) 2020-04-02
EP4327888A2 (en) 2024-02-28
US20250082661A1 (en) 2025-03-13
HUE042825T2 (hu) 2019-07-29
CN103479586A (zh) 2014-01-01
US10220050B2 (en) 2019-03-05
PL2299984T3 (pl) 2019-07-31
AU2015202884A1 (en) 2015-06-18
EP3782611B1 (en) 2022-07-06
US20090286752A1 (en) 2009-11-19
US11571436B2 (en) 2023-02-07
EP3782612B1 (en) 2023-11-08
US20230241086A1 (en) 2023-08-03
NZ602833A (en) 2014-04-30
AR071808A1 (es) 2010-07-14
PL3782611T3 (pl) 2022-11-07
JP6426778B2 (ja) 2018-11-21
TWI618538B (zh) 2018-03-21
CY1121350T1 (el) 2020-05-29
ES2893785T3 (es) 2022-02-10
US20150374732A1 (en) 2015-12-31
HRP20221064T1 (hr) 2022-11-11
AU2013202665B2 (en) 2015-06-25
EP2695609B1 (en) 2019-12-11
EP3782612A1 (en) 2021-02-24
US10646503B2 (en) 2020-05-12
CA2761582C (en) 2022-06-07
US20200316099A1 (en) 2020-10-08
KR101633134B1 (ko) 2016-06-23
SI3782611T1 (sl) 2022-10-28
RU2018109222A3 (es) 2021-07-02
TW201729817A (zh) 2017-09-01
CN102099018B (zh) 2016-01-13
LT3782611T (lt) 2022-10-10
TW201006478A (en) 2010-02-16
CL2013001097A1 (es) 2013-11-29
CN102099018A (zh) 2011-06-15
ES2774226T3 (es) 2020-07-17
EP2299984A1 (en) 2011-03-30
RU2010151428A (ru) 2012-06-20
HUE047707T2 (hu) 2020-05-28
AU2015202884B2 (en) 2017-02-23
FI3782612T3 (fi) 2024-01-16
PT2299984T (pt) 2019-02-25
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
ES2712506T3 (es) 2019-05-13
NZ589437A (en) 2012-11-30
BRPI0912717A2 (pt) 2014-12-23
SI3692983T1 (sl) 2021-11-30
CY1124720T1 (el) 2022-07-22
RU2018109222A (ru) 2019-09-17
US20220105118A1 (en) 2022-04-07
JP2017137326A (ja) 2017-08-10
DK2299984T3 (en) 2019-03-04
LT3692983T (lt) 2021-11-10
LT2299984T (lt) 2019-03-25
CA3094590A1 (en) 2009-11-19
HUE059635T2 (hu) 2022-12-28
CY1122681T1 (el) 2020-10-14
PL2695609T3 (pl) 2020-05-18
US20150056280A1 (en) 2015-02-26
PT3782612T (pt) 2024-01-18
US20230255996A1 (en) 2023-08-17
CN105535008A (zh) 2016-05-04
PT2695609T (pt) 2020-03-02
WO2009139888A1 (en) 2009-11-19
HRP20211398T1 (hr) 2021-12-10
IL238087B (en) 2019-01-31
NI201000193A (es) 2011-08-01
HUE064677T2 (hu) 2024-04-28
ES2969144T3 (es) 2024-05-16
US12053482B2 (en) 2024-08-06
PT3782611T (pt) 2022-11-18
TWI522103B (zh) 2016-02-21
JP2011520880A (ja) 2011-07-21
HRP20231439T1 (hr) 2024-03-01
HRP20200096T1 (hr) 2020-04-03
TW201513869A (zh) 2015-04-16
RU2476207C2 (ru) 2013-02-27
DK3782611T3 (da) 2022-09-05
HRP20190100T1 (hr) 2019-04-05
RU2012147739A (ru) 2014-05-20
EP2299984B1 (en) 2018-11-28
EP4327888A3 (en) 2024-05-22
AU2009246926B2 (en) 2014-06-26
US20180153916A1 (en) 2018-06-07
ECSP10010665A (es) 2011-01-31
SI2299984T1 (sl) 2019-04-30
DK3782612T3 (da) 2024-01-15
NZ623495A (en) 2015-08-28
EP2695609A1 (en) 2014-02-12
ZA201008229B (en) 2012-02-29
KR20110015629A (ko) 2011-02-16
PT3692983T (pt) 2021-11-08
EP3692983A1 (en) 2020-08-12
US20190231803A1 (en) 2019-08-01
AU2009246926A1 (en) 2009-11-19
RU2765076C2 (ru) 2022-01-25
CR11789A (es) 2011-02-21
JP2015110575A (ja) 2015-06-18
IL209307A (en) 2016-02-29
US10463683B2 (en) 2019-11-05
IL209307A0 (en) 2011-01-31
CN103479586B (zh) 2017-03-01
PE20142440A1 (es) 2015-01-28
ES2927556T3 (es) 2022-11-08
CA3094580A1 (en) 2009-11-19
JP6105547B2 (ja) 2017-03-29
MY161593A (en) 2017-04-28
MX363023B (es) 2019-03-05
SI2695609T1 (sl) 2020-03-31
HUE055911T2 (hu) 2021-12-28
EP3782611A1 (en) 2021-02-24
PL3692983T3 (pl) 2021-12-27
CA2761582A1 (en) 2009-11-19
EP3692983B1 (en) 2021-08-11
SI3782612T1 (sl) 2024-02-29
CA3094580C (en) 2021-05-18
CL2009001170A1 (es) 2010-06-04
MX2010012470A (es) 2010-12-02
US20220079964A1 (en) 2022-03-17
US8846628B2 (en) 2014-09-30
DK2695609T3 (da) 2020-02-10
AU2013202665A1 (en) 2013-05-02
LT3782612T (lt) 2023-12-27
LT2695609T (lt) 2020-02-10

Similar Documents

Publication Publication Date Title
DOP2010000387A (es) Compuestos pirazolicos 436
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
GT200500275A (es) Nuevos herbicidas
CL2009001170A1 (es) Composicion farmaceutica para administracion oral que comprende 5-azacitidina de liberacion inmediata sin recubrimiento enterico; y su uso para el tratamiento de una enfermedad asociada a la proliferacion anormal de celulas, tal como sindrome mielodisplasico, leucemia mielogena aguda y cancer de pulmon, entre otros.
CO6351785A2 (es) Inhibidores de cinasa map p39
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
CU20120171A7 (es) Triazolopiridinas sustituidas
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
CL2009000498A1 (es) Compuestos derivados de benzo [f][1,7]naftiridin sustituidos, moduladores de receptor toll; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedad infecciosa, inflamatoria, dermatologica, respiratoria o inmune.
NI201000041A (es) Derivados y composiciones que comprenden quinazolinona 6-, 7-, u 8 - sustituida y métodos para utilizar la misma.
CL2012001971A1 (es) Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras.
GT200500325A (es) Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa
ECSP13013087A (es) Compuestos para el tratamiento de la adicción
GT200600166A (es) Derivados de cromano y cromeno y usos de los mismos
AR045161A1 (es) Derivados de quinazolina
CR20120264A (es) Compuestos
PE20120476A1 (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
AR080295A1 (es) Composiciones para el cuidado bucal y metodos de tratamiento
UY29298A1 (es) Compuestos
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
HN2006020928A (es) "composiciones de tanaproget que contienen etinil estradiol"
UY31780A (es) Fenoxibenzamidas sustituidas

Legal Events

Date Code Title Description
FC Refusal